Status:
RECRUITING
A Global Study of the PETAL Consortium
Lead Sponsor:
Massachusetts General Hospital
Conditions:
T-Cell and NK-Cell Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagno...
Detailed Description
This study is a prospective, longitudinal observational study of patients with newly diagnosed or relapsed/refractory T-cell and NK-cell neoplasms, conducted across multiple participating institutions...
Eligibility Criteria
Inclusion
- Untreated, relapsed, or refractory histologically confirmed mature T-cell or NK-cell neoplasm.
- All subtypes of PTCL are eligible except for T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.
Exclusion
- Precursor T/NK neoplasms, T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.
- Adults who are unable to consent, individuals who are not yet adults such as infants, children and teenagers, pregnant women, and prisoners.
Key Trial Info
Start Date :
January 5 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06067347
Start Date
January 5 2024
End Date
January 1 2028
Last Update
November 12 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
3
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
4
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104